IP Verse

H. Lundbeck A/s opposition analysis

COMPANY ANALYSIS

Patent:

Grant Date:

Aug 21, 2024

Title:

Therapeutic Uses Of 1-[2-(2,4-Dimethyl-Phenylsulfanyl)Phenyl]Piperazine

Oppositions:

Patent:

Grant Date:

Jun 7, 2023

Title:

Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations

Oppositions:

Patent:

Grant Date:

Dec 15, 2021

Title:

Process For The Manufacture Of Vortioxetine Hbr Alpha-Form

Oppositions:

Patent:

Grant Date:

Jan 31, 2018

Title:

Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations

Oppositions:

Patent Number	Grant Date	Title	Total Oppositions
EP2608789	Aug 21, 2024	Therapeutic Uses Of 1-[2-(2,4-Dimethyl-Phenylsulfanyl)Phenyl]Piperazine	1
EP3345604	Jun 7, 2023	Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations	2
EP3615518	Dec 15, 2021	Process For The Manufacture Of Vortioxetine Hbr Alpha-Form	1
EP3138564	Jan 31, 2018	Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations	1

ALFRED E. TIEFENBACHER (GMBH & CO. KG)

BIOGARAN

GENERICS [UK] LIMITED

Feel free to send us a message here and we will get back to you